Literature DB >> 14673134

Mutations of the anti-mullerian hormone gene in patients with persistent mullerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model.

Corinne Belville1, Herman Van Vlijmen, Christian Ehrenfels, Blake Pepinsky, Alireza R Rezaie, Jean-Yves Picard, Nathalie Josso, Nathalie di Clemente, Richard L Cate.   

Abstract

Anti-Müllerian hormone (AMH), a TGF-beta family member, determines whether an individual develops a uterus and Fallopian tubes. Mutations in the AMH gene lead to persistent Müllerian duct syndrome in males. The wild-type human AMH protein is synthesized as a disulfide-linked dimer of two identical 70-kDa polypeptides, which undergoes proteolytic processing to generate a 110-kDa N-terminal dimer and a bioactive 25-kDa TGF-beta-like C-terminal dimer. We have studied the biosynthesis and secretion of wild-type AMH and of seven persistent Müllerian duct syndrome proteins, containing mutations in either the N- or C-terminal domain. Mutant proteins lacking the C-terminal domain are secreted more rapidly than full-length AMH, whereas single amino acid changes in both domains can have profound effects on protein stability and folding. The addition of a cysteine in an N-terminal domain mutant, R194C, prevents proper folding, whereas the elimination of the cysteine involved in forming the interchain disulfide bond, in a C-terminal domain mutant, C525Y, leads to a truncation at the C terminus. A molecular model of the AMH C-terminal domain provides insights into how some mutations could affect biosynthesis and function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673134     DOI: 10.1210/me.2003-0358

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  19 in total

1.  Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta.

Authors:  Nathalie di Clemente; Soazik P Jamin; Alexey Lugovskoy; Paul Carmillo; Christian Ehrenfels; Jean-Yves Picard; Adrian Whitty; Nathalie Josso; R Blake Pepinsky; Richard L Cate
Journal:  Mol Endocrinol       Date:  2010-09-22

Review 2.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

3.  Latent TGF-β structure and activation.

Authors:  Minlong Shi; Jianghai Zhu; Rui Wang; Xing Chen; Lizhi Mi; Thomas Walz; Timothy A Springer
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

4.  Persistent Mullerian duct syndrome: a rare cause of unilateral cryptorchidism.

Authors:  Laura Keukens; Gerda Zijp; Dick Mul
Journal:  BMJ Case Rep       Date:  2012-09-12

Review 5.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 6.  Anti-Müllerian Hormone Signal Transduction involved in Müllerian Duct Regression.

Authors:  Richard L Cate
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

Review 7.  Molecular Mechanisms of AMH Signaling.

Authors:  James A Howard; Kaitlin N Hart; Thomas B Thompson
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

8.  Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression.

Authors:  Joo Hyun Park; Yoshihiro Tanaka; Nelson A Arango; Lihua Zhang; L Andrew Benedict; Mi In Roh; Patricia K Donahoe; Jose M Teixeira
Journal:  Dev Biol       Date:  2013-12-19       Impact factor: 3.582

9.  A single base pair mutation encoding a premature stop codon in the MIS type II receptor is responsible for canine persistent Müllerian duct syndrome.

Authors:  Xiufeng Wu; Shengqin Wan; Shashikant Pujar; Mark E Haskins; Donald H Schlafer; Mary M Lee; Vicki N Meyers-Wallen
Journal:  J Androl       Date:  2008-08-21

10.  A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligands.

Authors:  Kelly L Walton; Yogeshwar Makanji; Matthew C Wilce; Karen L Chan; David M Robertson; Craig A Harrison
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.